The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gastrointestinal Disorder Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food. Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.
The global Gastrointestinal Disorder Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Disorder Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Gastrointestinal Disorder Therapeutics market. Irritable Bowel Syndrome (IBS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chronic Constipation (CC) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Disorder Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Disorder Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Disorder Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Disorder Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Disorder Therapeutics covered in this report include AstraZeneca, Takeda Pharmaceutical, Johnson & Johnson, Eisai, Abbott Laboratories, Salix Pharmaceuticals, Bausch Health, Allergan and Bayer, etc.
The global Gastrointestinal Disorder Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Takeda Pharmaceutical
Johnson & Johnson
Eisai
Abbott Laboratories
Salix Pharmaceuticals
Bausch Health
Allergan
Bayer
UCB
AbbVie
GlaxoSmithKline
Astellas Pharma
Global Gastrointestinal Disorder Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Disorder Therapeutics market, Segment by Type:
Irritable Bowel Syndrome (IBS)
Chronic Constipation (CC)
Ulcerative Colitis (UC)
Global Gastrointestinal Disorder Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Disorder Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food. Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.
The global Gastrointestinal Disorder Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Disorder Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Gastrointestinal Disorder Therapeutics market. Irritable Bowel Syndrome (IBS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chronic Constipation (CC) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Disorder Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Disorder Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Disorder Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Disorder Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Disorder Therapeutics covered in this report include AstraZeneca, Takeda Pharmaceutical, Johnson & Johnson, Eisai, Abbott Laboratories, Salix Pharmaceuticals, Bausch Health, Allergan and Bayer, etc.
The global Gastrointestinal Disorder Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Takeda Pharmaceutical
Johnson & Johnson
Eisai
Abbott Laboratories
Salix Pharmaceuticals
Bausch Health
Allergan
Bayer
UCB
AbbVie
GlaxoSmithKline
Astellas Pharma
Global Gastrointestinal Disorder Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Disorder Therapeutics market, Segment by Type:
Irritable Bowel Syndrome (IBS)
Chronic Constipation (CC)
Ulcerative Colitis (UC)
Global Gastrointestinal Disorder Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Disorder Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gastrointestinal Disorder Therapeutics
1.1 Gastrointestinal Disorder Therapeutics Market Overview
1.1.1 Gastrointestinal Disorder Therapeutics Product Scope
1.1.2 Gastrointestinal Disorder Therapeutics Market Status and Outlook
1.2 Global Gastrointestinal Disorder Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastrointestinal Disorder Therapeutics Market Size by Region (2018-2029)
1.4 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Gastrointestinal Disorder Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
1.6.1 North America Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
1.6.2 Europe Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
1.6.4 Latin America Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Size (2018-2029)
2 Gastrointestinal Disorder Therapeutics Market by Type
2.1 Introduction
2.1.1 Irritable Bowel Syndrome (IBS)
2.1.2 Chronic Constipation (CC)
2.1.3 Ulcerative Colitis (UC)
2.2 Global Gastrointestinal Disorder Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastrointestinal Disorder Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastrointestinal Disorder Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastrointestinal Disorder Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastrointestinal Disorder Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Breakdown by Type (2018-2029)
3 Gastrointestinal Disorder Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Gastrointestinal Disorder Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastrointestinal Disorder Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastrointestinal Disorder Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastrointestinal Disorder Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastrointestinal Disorder Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastrointestinal Disorder Therapeutics Revenue Breakdown by Application (2018-2029)
4 Gastrointestinal Disorder Therapeutics Competition Analysis by Players
4.1 Global Gastrointestinal Disorder Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastrointestinal Disorder Therapeutics as of 2022)
4.3 Date of Key Players Enter into Gastrointestinal Disorder Therapeutics Market
4.4 Global Top Players Gastrointestinal Disorder Therapeutics Headquarters and Area Served
4.5 Key Players Gastrointestinal Disorder Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Gastrointestinal Disorder Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.1.4 AstraZeneca Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Takeda Pharmaceutical
5.2.1 Takeda Pharmaceutical Profile
5.2.2 Takeda Pharmaceutical Main Business
5.2.3 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.2.4 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Takeda Pharmaceutical Recent Developments
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.3.4 Johnson & Johnson Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Eisai Recent Developments
5.4 Eisai
5.4.1 Eisai Profile
5.4.2 Eisai Main Business
5.4.3 Eisai Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.4.4 Eisai Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Eisai Recent Developments
5.5 Abbott Laboratories
5.5.1 Abbott Laboratories Profile
5.5.2 Abbott Laboratories Main Business
5.5.3 Abbott Laboratories Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.5.4 Abbott Laboratories Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Abbott Laboratories Recent Developments
5.6 Salix Pharmaceuticals
5.6.1 Salix Pharmaceuticals Profile
5.6.2 Salix Pharmaceuticals Main Business
5.6.3 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.6.4 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Salix Pharmaceuticals Recent Developments
5.7 Bausch Health
5.7.1 Bausch Health Profile
5.7.2 Bausch Health Main Business
5.7.3 Bausch Health Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.7.4 Bausch Health Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Bausch Health Recent Developments
5.8 Allergan
5.8.1 Allergan Profile
5.8.2 Allergan Main Business
5.8.3 Allergan Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.8.4 Allergan Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Allergan Recent Developments
5.9 Bayer
5.9.1 Bayer Profile
5.9.2 Bayer Main Business
5.9.3 Bayer Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.9.4 Bayer Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Bayer Recent Developments
5.10 UCB
5.10.1 UCB Profile
5.10.2 UCB Main Business
5.10.3 UCB Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.10.4 UCB Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 UCB Recent Developments
5.11 AbbVie
5.11.1 AbbVie Profile
5.11.2 AbbVie Main Business
5.11.3 AbbVie Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.11.4 AbbVie Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 AbbVie Recent Developments
5.12 GlaxoSmithKline
5.12.1 GlaxoSmithKline Profile
5.12.2 GlaxoSmithKline Main Business
5.12.3 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.12.4 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 GlaxoSmithKline Recent Developments
5.13 Astellas Pharma
5.13.1 Astellas Pharma Profile
5.13.2 Astellas Pharma Main Business
5.13.3 Astellas Pharma Gastrointestinal Disorder Therapeutics Products, Services and Solutions
5.13.4 Astellas Pharma Gastrointestinal Disorder Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Astellas Pharma Recent Developments
6 North America
6.1 North America Gastrointestinal Disorder Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gastrointestinal Disorder Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastrointestinal Disorder Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastrointestinal Disorder Therapeutics Market Dynamics
11.1 Gastrointestinal Disorder Therapeutics Industry Trends
11.2 Gastrointestinal Disorder Therapeutics Market Drivers
11.3 Gastrointestinal Disorder Therapeutics Market Challenges
11.4 Gastrointestinal Disorder Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
